These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 17310129

  • 1. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells.
    Zitzmann K, De Toni EN, Brand S, Göke B, Meinecke J, Spöttl G, Meyer HH, Auernhammer CJ.
    Neuroendocrinology; 2007; 85(1):54-60. PubMed ID: 17310129
    [Abstract] [Full Text] [Related]

  • 2. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer.
    Boulay A, Rudloff J, Ye J, Zumstein-Mecker S, O'Reilly T, Evans DB, Chen S, Lane HA.
    Clin Cancer Res; 2005 Jul 15; 11(14):5319-28. PubMed ID: 16033851
    [Abstract] [Full Text] [Related]

  • 3. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
    Gorshtein A, Rubinfeld H, Kendler E, Theodoropoulou M, Cerovac V, Stalla GK, Cohen ZR, Hadani M, Shimon I.
    Endocr Relat Cancer; 2009 Sep 15; 16(3):1017-27. PubMed ID: 19509067
    [Abstract] [Full Text] [Related]

  • 4. The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.
    Grozinsky-Glasberg S, Rubinfeld H, Nordenberg Y, Gorshtein A, Praiss M, Kendler E, Feinmesser R, Grossman AB, Shimon I.
    Mol Cell Endocrinol; 2010 Feb 05; 315(1-2):87-94. PubMed ID: 19815051
    [Abstract] [Full Text] [Related]

  • 5. Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line.
    Grozinsky-Glasberg S, Franchi G, Teng M, Leontiou CA, Ribeiro de Oliveira A, Dalino P, Salahuddin N, Korbonits M, Grossman AB.
    Neuroendocrinology; 2008 Feb 05; 87(3):168-81. PubMed ID: 18025810
    [Abstract] [Full Text] [Related]

  • 6. Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer.
    Manegold PC, Paringer C, Kulka U, Krimmel K, Eichhorn ME, Wilkowski R, Jauch KW, Guba M, Bruns CJ.
    Clin Cancer Res; 2008 Feb 01; 14(3):892-900. PubMed ID: 18245553
    [Abstract] [Full Text] [Related]

  • 7. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
    Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM, Martiny-Baron G, Schnell CR, Sini P, O'Reilly T.
    Clin Cancer Res; 2009 Mar 01; 15(5):1612-22. PubMed ID: 19223496
    [Abstract] [Full Text] [Related]

  • 8. RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer.
    Wang ZG, Fukazawa T, Nishikawa T, Watanabe N, Sakurama K, Motoki T, Hatakeyama S, Omori O, Ohara T, Tanabe S, Fujiwara Y, Takaoka M, Shirakawa Y, Yamatsuji T, Tanaka N, Naomoto Y.
    Oncol Rep; 2010 Apr 01; 23(4):1167-72. PubMed ID: 20204306
    [Abstract] [Full Text] [Related]

  • 9. Role of the novel mTOR inhibitor RAD001 (everolimus) in anaplastic thyroid cancer.
    Papewalis C, Wuttke M, Schinner S, Willenberg HS, Baran AM, Scherbaum WA, Schott M.
    Horm Metab Res; 2009 Oct 01; 41(10):752-6. PubMed ID: 19513966
    [Abstract] [Full Text] [Related]

  • 10. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro.
    Liu H, Zang C, Schefe JH, Schwarzlose-Schwarck S, Regierer AC, Elstner E, Schulz CO, Scholz C, Possinger K, Eucker J.
    Anticancer Res; 2011 Sep 01; 31(9):2713-22. PubMed ID: 21868512
    [Abstract] [Full Text] [Related]

  • 11. Akt and p53 are potential mediators of reduced mammary tumor growth by cloroquine and the mTOR inhibitor RAD001.
    Loehberg CR, Strissel PL, Dittrich R, Strick R, Dittmer J, Dittmer A, Fabry B, Kalender WA, Koch T, Wachter DL, Groh N, Polier A, Brandt I, Lotz L, Hoffmann I, Koppitz F, Oeser S, Mueller A, Fasching PA, Lux MP, Beckmann MW, Schrauder MG.
    Biochem Pharmacol; 2012 Feb 15; 83(4):480-8. PubMed ID: 22142888
    [Abstract] [Full Text] [Related]

  • 12. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
    Liu H, Scholz C, Zang C, Schefe JH, Habbel P, Regierer AC, Schulz CO, Possinger K, Eucker J.
    Anticancer Res; 2012 May 15; 32(5):1627-37. PubMed ID: 22593441
    [Abstract] [Full Text] [Related]

  • 13. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells.
    Treeck O, Wackwitz B, Haus U, Ortmann O.
    Gynecol Oncol; 2006 Aug 15; 102(2):292-9. PubMed ID: 16443261
    [Abstract] [Full Text] [Related]

  • 14. Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids.
    Zatelli MC, Minoia M, Martini C, Tagliati F, Ambrosio MR, Schiavon M, Buratto M, Calabrese F, Gentilin E, Cavallesco G, Berdondini L, Rea F, degli Uberti EC.
    Endocr Relat Cancer; 2010 Sep 15; 17(3):719-29. PubMed ID: 20554786
    [Abstract] [Full Text] [Related]

  • 15. RAD001 (everolimus) induces dose-dependent changes to cell cycle regulation and modifies the cell cycle response to vincristine.
    Saunders PO, Weiss J, Welschinger R, Baraz R, Bradstock KF, Bendall LJ.
    Oncogene; 2013 Oct 15; 32(40):4789-97. PubMed ID: 23128395
    [Abstract] [Full Text] [Related]

  • 16. Synergistic anti-tumor effects of RAD001 with MEK inhibitors in neuroendocrine tumors: a potential mechanism of therapeutic limitation of mTOR inhibitor.
    Iida S, Miki Y, Ono K, Akahira J, Nakamura Y, Suzuki T, Sasano H.
    Mol Cell Endocrinol; 2012 Mar 05; 350(1):99-106. PubMed ID: 22178087
    [Abstract] [Full Text] [Related]

  • 17. The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.
    Scholz A, Wagner K, Welzel M, Remlinger F, Wiedenmann B, Siemeister G, Rosewicz S, Detjen KM.
    Gut; 2009 Feb 05; 58(2):261-70. PubMed ID: 18829975
    [Abstract] [Full Text] [Related]

  • 18. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.
    Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O'Reilly T, Natt F, Hall J, Lane HA, Thomas G.
    Cell; 2005 Mar 25; 120(6):747-59. PubMed ID: 15797377
    [Abstract] [Full Text] [Related]

  • 19. In vivo and in vitro effects of RAD001 on bladder cancer.
    Vasconcelos-Nóbrega C, Pinto-Leite R, Arantes-Rodrigues R, Ferreira R, Brochado P, Cardoso ML, Palmeira C, Salvador A, Guedes-Teixeira CI, Colaço A, Palomino LF, Lopes C, Santos L, Oliveira PA.
    Urol Oncol; 2013 Oct 25; 31(7):1212-21. PubMed ID: 22169072
    [Abstract] [Full Text] [Related]

  • 20. RAD001 (everolimus) improves the efficacy of replicating adenoviruses that target colon cancer.
    Homicsko K, Lukashev A, Iggo RD.
    Cancer Res; 2005 Aug 01; 65(15):6882-90. PubMed ID: 16061672
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.